COMMUNIQUÉS West-GlobeNewswire
-
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
23/12/2025 -
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
23/12/2025 -
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
23/12/2025 -
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
23/12/2025 -
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
23/12/2025 -
CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
23/12/2025 -
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
23/12/2025 -
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
23/12/2025 -
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique
23/12/2025 -
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
23/12/2025 -
Vireo Growth Inc. Enters California and Florida and Strengthens Delivery Platforms with Acquisition of Eaze Inc.
23/12/2025 -
Burning Rock Announces Results of 2025 Annual General Meeting
23/12/2025 -
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025 -
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
23/12/2025 -
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025 -
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025 -
Apollomics Reports First Half 2025 Financial Results
22/12/2025 -
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025 -
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
22/12/2025
Pages